483
CellTrans Inc.CellTrans Inc. – FDA 483, Jun 11, 2021
Record Details
An FDA inspection of CellTrans Islet Isolation facility in Chicago, IL, revealed significant deficiencies across its quality unit, aseptic processing, and manufacturing controls. The firm was cited for issues including inadequate sterilization oversight, deficient deviation reporting, release of non-conforming product lots, and poor environmental controls. These observations highlight a systemic lack of adherence to established quality standards and procedures.
View Company Profile
ID · eabc837b-2080-42d9-8ede-acc82db8982e
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.